Clinical trial of MEDI 5117 as a potential therapy for rheumatoid arthritis.

Trial Profile

Clinical trial of MEDI 5117 as a potential therapy for rheumatoid arthritis.

Planning
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs WBP-216 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jan 2017 According to WuXi AppTec media release, an Investigational New Drug (IND) application of WBP216 (MEDI5117) for rheumatoid arthritis (RA) and other autoimmune disorders has been approved by the China Food and Drug Administration (CFDA).
    • 31 Mar 2015 New trial record
    • 27 Mar 2015 An IND has been accepted for review by the China Food and Drug Administration, according to a WuXi PharmaTech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top